Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Teva Sees COVID Sales Correction

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Sales & Earnings Strategy

Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.

Biosimilars Strategy

Who’s Hired? ANI Names New CEO

ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.

Appointments Strategy

Teva Still Hopes To Reach Deal On US Price-Fixing Allegations

Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.

Legal Issues Pricing Strategies

Teva And Alvotech Strike US Biosimilars Pact

Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.

Deals Biosimilars

Adalvo Partners With AmbioPharm For Several Complex Products

Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.

Deals Manufacturing
See All
UsernamePublicRestriction

Register